Obsidian Therapeutics to Present Preclinical Data Supporting OBX-115 and CytoDRiVE Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
BMO Capital Maintains Obsidian Energy Ltd(OBE.US) With Buy Rating, Raises Target Price to $12.24
RBC Capital Maintains Obsidian Energy Ltd(OBE.US) With Buy Rating, Raises Target Price to $9.36
Obsidian Energy Q3 2024 GAAP EPS C$1.58 Beats C$1.06 Estimate
Obsidian Energy Has Outperform Rating, $13 Price Target Confirmed at RBC Capital Markets
Philips Posts Weak Earnings, Joins Clear Channel Outdoor And Other Big Stocks Moving Lower In Monday's Pre-Market Session